| Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation B Sangro, L Carpanese, R Cianni, R Golfieri, D Gasparini, S Ezziddin, ... Hepatology 54 (3), 868-878, 2011 | 614 | 2011 |
| Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival RT Hoffmann, PM Paprottka, A Schön, F Bamberg, A Haug, EM Dürr, ... Cardiovascular and interventional radiology 35 (1), 105-116, 2012 | 222 | 2012 |
| Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours A Haug, CJ Auernhammer, B Wängler, R Tiling, G Schmidt, B Göke, ... European journal of nuclear medicine and molecular imaging 36 (5), 765-770, 2009 | 215 | 2009 |
| 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor–mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors AR Haug, CJ Auernhammer, B Wängler, GP Schmidt, C Uebleis, B Göke, ... Journal of nuclear medicine 51 (9), 1349-1356, 2010 | 204 | 2010 |
| In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors A Rominger, T Saam, E Vogl, C Übleis, C la Fougère, S Förster, A Haug, ... Journal of nuclear medicine 51 (2), 193-197, 2010 | 154 | 2010 |
| Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG–PET–CT GP Schmidt, A Baur-Melnyk, A Haug, V Heinemann, I Bauerfeind, ... European journal of radiology 65 (1), 47-58, 2008 | 152 | 2008 |
| The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors AR Haug, R Cindea-Drimus, CJ Auernhammer, M Reincke, B Wängler, ... Journal of nuclear medicine 53 (11), 1686-1692, 2012 | 149 | 2012 |
| Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma FT Kolligs, JI Bilbao, T Jakobs, M Iñarrairaegui, JM Nagel, M Rodriguez, ... Liver international 35 (6), 1715-1721, 2015 | 121 | 2015 |
| Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma C la Fougère, W Hundt, N Bröckel, T Pfluger, A Haug, B Scher, M Hacker, ... European journal of nuclear medicine and molecular imaging 33 (12), 1417-1425, 2006 | 121 | 2006 |
| Current status of theranostics in prostate cancer I Virgolini, C Decristoforo, A Haug, S Fanti, C Uprimny European journal of nuclear medicine and molecular imaging 45 (3), 471-495, 2018 | 120 | 2018 |
| Detection of low-grade prosthetic joint infections using 99mTc-antigranulocyte SPECT/CT: initial clinical results V Graute, M Feist, S Lehner, A Haug, PE Müller, P Bartenstein, M Hacker European journal of nuclear medicine and molecular imaging 37 (9), 1751-1759, 2010 | 116 | 2010 |
| Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue W Rachinger, VM Stoecklein, NA Terpolilli, AR Haug, L Ertl, J Pöschl, ... Journal of Nuclear Medicine 56 (3), 347-353, 2015 | 112 | 2015 |
| Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres PM Paprottka, RT Hoffmann, A Haug, WH Sommer, F Raeßler, CG Trumm, ... Cardiovascular and interventional radiology 35 (2), 334-342, 2012 | 112 | 2012 |
| Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer GP Schmidt, A Baur-Melnyk, A Haug, S Utzschneider, CR Becker, R Tiling, ... European radiology 19 (6), 1366-1378, 2009 | 109 | 2009 |
| 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer AR Haug, BPT Donfack, C Trumm, CJ Zech, M Michl, RP Laubender, ... Journal of Nuclear Medicine 53 (3), 371-377, 2012 | 104 | 2012 |
| Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma R Golfieri, JI Bilbao, L Carpanese, R Cianni, D Gasparini, S Ezziddin, ... Journal of hepatology 59 (4), 753-761, 2013 | 97 | 2013 |
| PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact B Grubmüller, P Baltzer, S Hartenbach, D D’Andrea, TH Helbich, ... Clinical Cancer Research 24 (24), 6300-6307, 2018 | 93 | 2018 |
| Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer WP Fendler, DBP Tiega, H Ilhan, PM Paprottka, V Heinemann, TF Jakobs, ... Journal of Nuclear Medicine 54 (8), 1202-1208, 2013 | 93 | 2013 |
| Whole-body MRI and PET-CT in the management of cancer patients GP Schmidt, AR Haug, SO Schoenberg, MF Reiser European radiology 16 (6), 1216-1225, 2006 | 92 | 2006 |
| 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy–diagnostic performance and impact on therapeutic decision-making B Grubmüller, P Baltzer, D D’andrea, S Korn, AR Haug, M Hacker, ... European journal of nuclear medicine and molecular imaging 45 (2), 235-242, 2018 | 91 | 2018 |
